Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 95%
filed 2026-07-31
The filing discloses entry into private placement agreements for the unregistered sale of 677,084 shares of common stock at $4.80 per share for approximately $3.25 million in aggregate gross proceeds. Items 1.01 and 3.02 explicitly describe the issuance as unregistered equity securities expected to be issued under Regulation S, which is a classic dilutive issuance. The involvement of related parties (the CEO's brothers) and the use of proceeds for general corporate purposes and potential strategic investments further support materiality to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-31
Clean Energy Technologies entered into a securities purchase agreement with 1800 Diagonal Lending LLC to issue a convertible promissory note with principal of $147,840 for net funding of $125,000. The note is convertible into common stock at 85% of the lowest closing bid price, with conversion restrictions tied to beneficial ownership thresholds and Nasdaq Rule 5635(d) shareholder approval requirements. Item 3.02 explicitly discloses this as an unregistered sale of equity securities under Section 4(a)(2), and the convertible feature creates dilutive equity exposure typical of PIPE-like financing arrangements at small-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-31
The filing discloses unregistered sales of equity securities under Item 3.02, including issuance of pre-funded warrants to purchase 12,131,770 shares (representing a significant dilution) and 123,537 shares of common stock to service providers. The pre-funded warrants have an exercise price of $0.0001 per share and are contingent on stockholder approval for issuance in excess of 19.99% of outstanding common stock, indicating substantial dilutive potential. This is a classic private placement structure typical of small-cap equity raises.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-31
Item 8.01
The Item 8.01 disclosure centers on two material events: (1) a $54.6M ten-year contract award (operational/strategic), and (2) a warrant inducement transaction involving $4.5M in gross proceeds and issuance of 5,012,159 new unregistered warrants at 150% of exercised warrants. The warrant issuance is a dilutive equity transaction requiring shareholder approval, fitting the dilutive_issuance category. While the contract award is also material, the warrant transaction is the more legally and financially significant disclosure requiring 8-K Item 8.01 treatment as an "other event."
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-31
Item 8.01
Healthcare Realty Trust filed a new automatic shelf registration statement and prospectus supplement on July 31, 2026, establishing an at-the-market (ATM) equity offering program with an aggregate gross sales price of up to $1,000,000,000 in Class A common stock. The filing of an ATM prospectus supplement with a substantial offering capacity represents a material dilutive issuance event, as it creates the mechanism for future equity sales that could dilute existing shareholders. The $1 billion offering capacity is material to a REIT of this size.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-31
Item 3.02
The Company completed a private placement of 386,500 units at $10.00 per unit ($3.865 million gross proceeds) to the sponsor Pelican II Capital Solutions Limited and EarlyBirdCapital, Inc., pursuant to Section 4(a)(2) exemption, concurrent with the IPO closing.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-31
Item 3.02
The Fund completed an unregistered private placement of limited partnership units totaling approximately $17.85 million to third-party investors on July 1, 2026, structured across multiple unit classes and series, exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-30
Item 7.01
Sky Quarry disclosed completion of an at-the-market (ATM) equity offering program under which it issued approximately 4.4 million shares of common stock and raised approximately $13.5 million in net proceeds between April and June 2026. The disclosure details the sales agreement with Cantor Fitzgerald and the subsequent amended agreement with Muriel Siebert & Co., and specifies the number of shares sold and proceeds generated under each arrangement. This is a material dilutive issuance of equity securities that would affect a reasonable investor's assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-30
Item 1.01
NanoViricides completed a registered direct offering on July 27, 2026, selling 2,416,339 shares of common stock at $1.53 per share, pre-funded warrants, and common warrants to purchase 2,516,339 additional shares for approximately $3.8 million in gross proceeds. The offering was announced on July 24, 2026, pursuant to an effective Form S-3 shelf registration statement and includes a 60-day lock-up on further issuances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-30
Item 3.02
The Company issued unregistered Common Stock pursuant to the Letter Agreement, relying on Section 4(a)(2) exemption from Securities Act registration. The shares are subject to restrictive legends and represent a material dilutive issuance affecting the Company's capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-30
Item 8.01
Yarrow Bioscience entered into an exchange agreement on July 29, 2026, whereby an existing stockholder exchanged 133,290 shares of common stock for pre-funded warrants to purchase 133,290 shares at $0.0001 per share. The transaction results in the issuance of unregistered securities (pre-funded warrants) relying on Section 3(a)(9) exemption, and materially increases dilution: post-exchange, the company will have 2,669,788 shares outstanding but pre-funded warrants to purchase 25,914,530 additional shares. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of ownership and voting power.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-30
EX-99.1
NetClass Technology Inc agreed to grant 320,000 Class A ordinary shares to China Outdoor Media Development Limited as consideration for outdoor advertising services, with issuance expected by end of July 2026. This unregistered equity issuance is material to existing shareholders' ownership and voting interests.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-30
EX-99.1
This press release announces the pricing of an underwritten public offering of 1,491,305 common shares at US$4.00 per share for gross proceeds of US$6.0 million, with an additional over-allotment option for 223,695 shares. This is a registered equity issuance that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-30
The 6-K discloses the closing of a registered direct offering of 66,666,667 ordinary shares for approximately $30 million gross proceeds on July 29, 2026. This is a material equity issuance that dilutes existing shareholders and raises capital for the company's commercialization efforts. The offering was conducted pursuant to an effective Form F-3 registration statement, making it a registered (not unregistered) offering, but it remains a material capital-raising event that would affect a reasonable investor's assessment of ownership dilution and the company's financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-30
Item 3.02
The Company sold 113,268.541 Class I common shares for approximately $2.3 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D/S, representing a material capital raise that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-30
Item 8.01
The Company is conducting a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $1.1 million in subscriptions received on July 1, 2026, and an intent to continue monthly offerings at NAV.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-30
Item 8.01
The Company is conducting a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $7.1 million in subscriptions received on July 1, 2026, and an intention to continue selling shares monthly at NAV.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-30
The 6-K discloses a private placement of units consisting of Class A ordinary shares and warrants for aggregate gross proceeds of approximately US$10 million, entered into on July 29, 2026. This is an unregistered equity issuance with dilutive characteristics (warrants exercisable at US$4.40 per share), fitting the definition of a dilutive_issuance. The materiality is clear given the size of the offering and the warrant component that creates future dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-30
Item 3.02
Game Your Game Inc. completed the second closing of an unregistered sale of 8,000 shares of Series A convertible preferred stock to Streeterville Capital for $8,000,000 under Section 4(a)(2) and Regulation D Rule 506(b). The preferred shares are convertible into common stock at $8.00 per share and carry seniority over common stock with covenants restricting company actions without Required Holder consent, materially subordinating existing shareholders' rights and creating significant dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-30
Item 3.02
LogicMark entered into a Securities Purchase Agreement on July 28, 2026 to sell 250,000 shares of Series J Convertible Preferred Stock at $1.00 per share in a private placement closed July 30, 2026. The Series J Preferred Shares are convertible into common stock at a conversion price equal to 50% of the lowest traded price during the 30 trading days prior to conversion notice, creating significant dilution potential for existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-30
Item 3.02
Partners Group Lending Fund, LLC issued 131,244 Class M units for $196,013 pursuant to Section 4(a)(2) and Regulation D exemptions to accredited investors, representing an unregistered equity issuance that dilutes existing unitholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-30
EX-99.1
Anfield Energy announces the pricing of an underwritten public offering of 1,491,305 common shares at US$4.00 per share for aggregate gross proceeds of US$6.0 million, with an over-allotment option for an additional 223,695 shares. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-30
The filing discloses entry into a $1,000,000 convertible promissory note with Investments AKA, LLC (owned by Andre Agassi, the company's largest beneficial stockholder) under Item 1.01 and Item 3.02. The note will automatically convert into equity securities upon a future equity financing of at least $3,000,000, and the securities were issued without registration under Section 4(a)(2) and Rule 506(b). This is a dilutive unregistered equity issuance that raises capital and creates future dilution upon conversion, fitting the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-30
Item 3.02
The Company sold approximately 1,612,698 units of LLC interests for $31.7 million pursuant to subscription agreements and drawdown notices, with the issuance exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 91%
filed 2026-07-30
EX-99.1
Bitzero Holdings Inc. closed a US$25 million private placement of 5,828,342 special warrants at US$4.25 per warrant under Section 4(a)(2) of the Securities Act and Regulation D. The special warrants automatically convert into common shares and additional warrants, with warrant holders entitled to acquire common shares at US$5.00 per share for five years. The proceeds are intended for debt repayment, product development, acquisitions, and working capital.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-29
EX-99.1
Bitzero announced a private placement of 5,828,342 special warrants at US$4.25 per warrant for aggregate gross proceeds of approximately US$25 million. Each special warrant automatically converts into one common share and one common share purchase warrant, creating significant dilution to existing shareholders. The securities are being offered under Section 4(a)(2) of the U.S. Securities Act and Rule 506(b) of Regulation D as an unregistered private placement, which is the hallmark of a dilutive issuance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
EX-99.1
Liberty Defense issued 23,306 common shares at $4.55 per share to settle CAD$117,000 of indebtedness with a service provider. This is an unregistered equity issuance (shares subject to a four-month statutory hold period and explicitly noted as not registered under the U.S. Securities Act of 1933) that dilutes existing shareholders. The transaction converts debt to equity, which is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Item 3.02
BNB Plus Corp. issued 200,000 shares of Series B-1 Convertible Preferred Stock in an unregistered private placement relying on Section 4(a)(2) of the Securities Act as part of the settlement with Cypress parties.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
EX-99.1
The Trust announced an updated at-the-market (ATM) equity program to issue up to U.S.$250 million of Units, replacing a prior ATM program terminated in May 2026. This is a material dilutive issuance of equity securities in the form of Units of the Trust, authorized through an amended and restated sales agreement with multiple agents. The magnitude ($250 million) and the explicit authorization to issue new Units at market prices constitute a dilutive capital raise that would materially affect investor assessment of ownership dilution and the Trust's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 1.01
LB Pharmaceuticals entered into a Securities Purchase Agreement on July 28, 2026, to issue 3,577,560 shares of common stock and pre-funded warrants to purchase 715,513 additional shares in a private placement for approximately $150 million in gross proceeds at $34.94 per share to institutional investors under Section 4(a)(2) exemption without registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
Macquarie Infrastructure Fund sold approximately $25.4 million of unregistered limited partnership units on July 1, 2026, to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D exemptions, representing a significant capital raise and expansion of the Fund's equity base.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
Inhibikase issued a pre-funded warrant to acquire 18,030,000 shares of common stock without registration, relying on Section 3(a)(9) of the Securities Act. The warrant has a nominal $0.001 exercise price and is immediately exercisable, making it economically equivalent to a direct equity issuance. This is a classic dilutive unregistered equity transaction that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
The filing discloses an unregistered sale of approximately 1.5 million common units for $29.7 million pursuant to subscription agreements with existing unitholders, relying on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive issuance of equity securities to accredited investors under a capital drawdown mechanism, material to investors as it represents a significant capital raise and dilution event for the fund.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
Healthcare Triangle issued 12,546,540 unregistered shares of common stock on July 28, 2026, comprising 9,718,373 shares to Teyame AI LLC entities and 2,828,167 shares to SecureKloud Technologies Ltd. counterparties, both in reliance on Section 4(a)(2) and Regulation D exemptions. This represents a substantial dilutive issuance that increased outstanding shares from approximately 2.1 million to 14.6 million—a material capital event disclosed under Item 3.02 and explicitly highlighted in the press release as strengthening the company's Nasdaq listing compliance position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-29
The 6-K discloses entry into securities purchase agreements on July 17, 2026, for the issuance and sale of 20,000,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $200.0 million. The offering closed on July 29, 2026. This is a material registered equity issuance that dilutes existing shareholders and raises substantial capital for AI computing center development. The transaction meets the definition of dilutive_issuance under Item 3.02 equivalent disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
The Company completed an unregistered private placement of 270,000 Private Placement Units to the Sponsor at $10.00 per unit ($2.7 million aggregate) pursuant to Section 4(a)(2) exemption, concurrent with the IPO closing on July 27, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Item 3.02
The Company issued 360,000 shares of common stock (Commitment Shares) as consideration under a Forbearance Letter Agreement, pursuant to Section 4(a)(2) of the Securities Act of 1933, in connection with the financing transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-07-29
Item 1.01
Onconetix entered into a Securities Purchase Agreement to issue 37,812 shares of Series F convertible preferred stock for $30.2 million, with conversion rights into common stock at $0.9767 per share, and established a committed equity facility (ELOC) allowing purchases of up to $750 million in common stock. The unregistered sale relies on Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, representing a private investment in public equity (PIPE) transaction that materially dilutes existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Banco Bradesco announced a capital increase of R$ 10 billion through issuance of 302.9 million new common shares and 302.0 million new preferred shares at specified prices (R$ 15.43 and R$ 17.64 respectively), offered for private subscription to existing shareholders with preemptive rights. This is a material dilutive equity issuance that would affect shareholder ownership percentages and is disclosed as a discrete corporate action resolved by the Board on July 29, 2026.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Banco Bradesco announced approval of a capital increase of up to BRL 10 billion (minimum BRL 8 billion) through private subscription of new shares, with controlling shareholders committing to subscribe. The issuance of up to 604.9 million new shares (302.9 million common and 302.0 million preferred) at specified prices represents a material dilutive equity issuance. The filing explicitly discloses preemptive rights, issue pricing methodology, and allocation of proceeds to strategic investments and capitalization, all hallmarks of a dilutive equity capital raise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-29
Item 3.02
Processa completed a concurrent private placement of approximately $200 million in Series A convertible preferred stock (163,774.679 shares at $1,221.19 per share) to institutional investors under Section 4(a)(2), with PIPE investors owning approximately 52.6% of Processa on a fully-diluted basis post-closing.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-29
EX-99.1
VivoPower announced a US$50 million private investment in public equity (PIPE) structured as convertible preference shares converting at US$7.50 per share into Class A Ordinary Shares, with participation from institutional investors and entities associated with the CEO. This is a classic dilutive issuance of convertible securities that will result in equity dilution upon conversion, material to investors assessing capital structure and ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
The filing discloses an unregistered sale of 32,110 shares of common stock to a service provider at $3.27 per share under Section 4(a)(2) of the Securities Act. This is a classic dilutive issuance—an unregistered equity sale relying on the private offering exemption. Item 3.02 is the designated disclosure item for such transactions, and the language explicitly references the exemption from registration requirements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
The filing discloses a private placement of 250,000 shares of common stock at $4.80 per share for approximately $1.2 million in aggregate proceeds under a Private Placement Agreement with Pinnacle Partners Inc., with the shares issued in reliance on Regulation S (offshore transaction). This is a classic unregistered equity issuance disclosed under both Item 1.01 (Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), which is material to investors as it represents dilution and capital raising activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
HCW Biologics entered into a Securities Purchase Agreement on July 29, 2026, to issue 618,682 units comprising 218,682 shares of common stock and 400,000 pre-funded warrants, plus common warrants contingent on stockholder approval, for approximately $1.6 million in gross proceeds. This is a classic private placement of equity securities by an emerging growth company raising capital, disclosed under Items 1.01 and 3.02, with the pre-funded warrants and common warrants representing significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-29
The filing discloses conversion notices from three directors (Casamento, Demesmin, and Goldman) electing to convert remaining outstanding principal amounts totaling approximately $466,000 under Convertible Bridge Notes into common stock. While the conversions are conditional on the stock price reaching $0.50 and insider trading compliance, this represents a material dilutive issuance of equity that will occur upon satisfaction of those conditions. The event is disclosed under Item 8.01 (Other Events) rather than Item 3.02, but the substance is a dilutive equity issuance by insiders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-29
The 6-K discloses an At The Market Offering Agreement under which Fusion Fuel Green PLC may offer and sell Class A Ordinary Shares through H.C. Wainwright & Co., LLC. The Company has already sold 256,597 shares for approximately $2.8 million and filed a prospectus supplement on July 29, 2026 relating to the offer and sale of up to $6.6 million in additional Class A Ordinary Shares. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-29
Item 3.02
VistaOne, L.P. disclosed an unregistered sale of approximately $42.2 million in limited partnership units across multiple unit classes (B, I, R, and S) as of July 1, 2026, exempt from Securities Act registration under Section 4(a)(2), Regulation D, and Regulation S. This private placement represents a material dilutive issuance to existing unitholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-28
Item 1.01
Dynex Capital amended its at-the-market (ATM) distribution agreement on July 28, 2026, increasing the number of shares available for sale by 80,000,000 shares to a total of 301,292,973 shares, with 99,326,438 shares remaining available for issuance. This is a dilutive equity issuance under an ATM program, which is a classic signal of capital raising at small- and mid-cap issuers and would materially affect shareholder equity and voting power.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-28
EX-99.1
Instinct Bio announced entry into an indicative term sheet for a proposed equity purchase facility allowing the company to sell up to $150 million of common stock over three years at VWAP-based pricing with a discount. This is a material dilutive equity issuance arrangement that would provide discretionary capital to the company, typical of PIPE-like or ATM-style offerings used by smaller biotechnology companies to raise cash. The $150 million size and three-year duration make this material to investors assessing capital structure and dilution risk.
View raw filing on EDGAR →